Lenzetto (Estradiol)

Estradiol binds to intracellular estrogen receptors ERα and ERβ after entering the bloodstream from the patch. This binding triggers gene transcription that restores estrogenic activity in tissues like the brain, bone, breast, and genital tract, thereby reducing vasomotor symptoms and supporting tissue maintenance.

The prescribed dose of Lenzetto is determined by the treating physician based on the individual’s clinical condition, severity of symptoms, and response to therapy. The healthcare professional selects the appropriate patch strength and application schedule for each patient.

Lenzetto is not recommended for use during pregnancy because estradiol can affect fetal development. It is also generally avoided while breastfeeding, as estrogen may pass into breast milk and influence milk production. Women who are pregnant, planning pregnancy, or nursing should discuss alternative options with their clinician.

To request Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenzetto delivers estradiol continuously through the skin, offering more stable plasma levels than oral tablets, which undergo first‑pass metabolism. This transdermal route can reduce hepatic side effects and may provide better symptom control for some women, while oral formulations may be preferred when patch adhesion is problematic.

Store Lenzetto patches at room temperature, below 25 °C, in their original sealed pouch. Keep them away from direct sunlight, moisture, and excessive heat. Do not fold or crush the patch, and discard any patch that appears damaged or discolored.

The patch is applied to clean, dry, hair‑free skin on the lower abdomen or buttock. Press firmly for several seconds to ensure good contact, then leave it in place for the prescribed duration, usually one week, before replacing it with a new patch at a different site.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions like anaphylaxis. Patients should seek immediate medical attention if they experience sudden leg pain, shortness of breath, chest pain, neurological deficits, or signs of a severe allergic response.

Lenzetto is contraindicated in women with a history of estrogen‑dependent cancers, unexplained vaginal bleeding, active or past thromboembolic disease, severe liver dysfunction, or known hypersensitivity to estradiol or patch components. Pregnant women and those planning pregnancy should also avoid its use.